Latest Lead News

Wiseway Group has reported a striking 66% increase in revenue for FY25, driven by robust expansion in its Imports and Overseas divisions alongside a nearly sevenfold rise in net profit before tax.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

Archer Materials has made notable advances in its quantum computing and biosensor technologies during FY25, alongside leadership changes and a widened net loss. The company’s progress signals growing momentum in its commercialisation efforts.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

Future Generation Global Limited has reported a 20.8% increase in its investment portfolio over the past year, prompting a boost in its fully franked interim dividend to 4.0 cents per share. This performance outpaces global market averages and underscores the company's sustainable investment approach.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Future Generation Australia reports a notable drop in half-year profits for 2025 but announces an increased fully franked interim dividend, reflecting confidence in its long-term investment strategy and social impact commitments.

MA Credit Income Trust has closed its Shortfall Offer ahead of schedule after demand exceeded the $190.5 million target, while updating the timetable for its upcoming Entitlement Offer.

Core Lithium Ltd has launched a non-underwritten equity raising to secure approximately A$60 million, aiming to advance its Finniss Lithium Project to a final investment decision. The capital raise includes a two-tranche placement and a share purchase plan, supporting operational readiness and strategic funding efforts.

Core Lithium has successfully raised $50 million through a two-tranche institutional placement, complemented by a $10 million Share Purchase Plan, to accelerate its Finniss Lithium Project towards a Final Investment Decision.